The Pittsburgh Life Sciences Greenhouse last week announced that Peter DeComo, John Kuzmishin, John Miclot, and Elizabeth Woo have joined the PLSG board of directors.
DeComo is co-founder, chairman, and CEO of Renal Solutions, and previously served as COO of HemoTherapies and senior vice president of the specialty pharma division of Olsten Health Services, now Accredo.
Kuzmishin is vice president of strategic business initiatives for the University of Pittsburgh Medical Center. Prior to joining UPMC in 2004, Kuzmishin spent 15 years as a healthcare investment banker, most recently as head of Robert W. Baird.
Miclot is president and CEO of Respironics, and has served as president of the homecare division of the company. Miclot joined Respironics in 1998 when it acquired Healthdyne Technologies, where he had served as senior vice president of sales and marketing.
Woo is currently vice president, biotechnology, for Thermo Fisher Scientific. Prior to this, Woo held positions as director of marketing, senior director of business development, senior director of technical marketing, and product manager.
BioSante Pharmaceuticals said last week that it has named Joy Thomas as vice president of corporate development strategies.
Thomas will be responsible for all corporate development strategy, including collaborations and licensing. She joins BioSante after 13 years with Baxter Healthcare, where she was most recently global strategy and business developer in the renal division.
Richard Myers, chair of genetics at the Stanford University School of Medicine and director of the Stanford Human Genome Center, will be leaving Stanford next year to serve as scientific director of the HudsonAlpha Institute for Biotechnology in Huntsville, Ala., Alabama Governor Bob Riley said last week.
Myers, an Alabama native, will move slowly from a consulting role over the coming year before he takes on the full-time position next fall. Meantime, he will continue his work running the Stanford HGC and as a professor at the university.
Maryland Governor Martin O’Malley has tapped Human Genome Sciences’ CEO Thomas Watkins to chair the state’s Life Sciences Advisory Board. The state has also selected more than a dozen other individuals from the life sciences, technology, real estate, regulatory, and academic spheres to serve on the board.
Among the other members are Janet Woodcock, deputy commissioner and chief medical officer of the US Food and Drug Administration; and David Ramsay, president of the University of Maryland, Baltimore.